Literature DB >> 11479630

Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.

Y Takebayashi1, P Pourquier, D B Zimonjic, K Nakayama, S Emmert, T Ueda, Y Urasaki, A Kanzaki, S I Akiyama, N Popescu, K H Kraemer, Y Pommier.   

Abstract

While investigating the novel anticancer drug ecteinascidin 743 (Et743), a natural marine product isolated from the Caribbean sea squirt, we discovered a new cell-killing mechanism mediated by DNA nucleotide excision repair (NER). A cancer cell line selected for resistance to Et743 had chromosome alterations in a region that included the gene implicated in the hereditary disease xeroderma pigmentosum (XPG, also known as Ercc5). Complementation with wild-type XPG restored the drug sensitivity. Xeroderma pigmentosum cells deficient in the NER genes XPG, XPA, XPD or XPF were resistant to Et743, and sensitivity was restored by complementation with wild-type genes. Moreover, studies of cells deficient in XPC or in the genes implicated in Cockayne syndrome (CSA and CSB) indicated that the drug sensitivity is specifically dependent on the transcription-coupled pathway of NER. We found that Et743 interacts with the transcription-coupled NER machinery to induce lethal DNA strand breaks.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11479630     DOI: 10.1038/91008

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  83 in total

1.  Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies.

Authors:  Lia Gore; E Rivera; M Basche; S L Moulder-Thompson; J Li; S Eppers; S Grolnic; C O'Bryant; D Cleere; Y A Elsayed; S G Eckhardt
Journal:  Invest New Drugs       Date:  2011-09-20       Impact factor: 3.850

2.  PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity.

Authors:  J F M Leal; M Martínez-Díez; V García-Hernández; V Moneo; A Domingo; J A Bueren-Calabuig; A Negri; F Gago; M J Guillén-Navarro; P Avilés; C Cuevas; L F García-Fernández; C M Galmarini
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

3.  Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach.

Authors:  M Tavecchio; C Natoli; P Ubezio; E Erba; M D'Incalci
Journal:  Cell Prolif       Date:  2007-12       Impact factor: 6.831

Review 4.  Drug development from marine natural products.

Authors:  Tadeusz F Molinski; Doralyn S Dalisay; Sarah L Lievens; Jonel P Saludes
Journal:  Nat Rev Drug Discov       Date:  2008-12-19       Impact factor: 84.694

5.  Molecular basis of differentiation therapy for soft tissue sarcomas.

Authors:  Gaurav Luther; Richard Rames; Eric R Wagner; Gaohui Zhu; Qing Luo; Yang Bi; Stephanie H Kim; Jian-Li Gao; Enyi Huang; Ke Yang; Linyuan Wang; Xing Liu; Mi Li; Ning Hu; Yuxi Su; Xiaoji Luo; Liang Chen; Jinyong Luo; Rex C Haydon; Hue H Luu; Lan Zhou; Tong-Chuan He
Journal:  Trends Cancer Res       Date:  2010

6.  Regioselectivity of Pictet-Spengler Cyclization Reactions to Construct the Pentacyclic Frameworks of the Ecteinascidin-Saframycin Class of Tetrahydroisoquinoline Antitumor Antibiotics.

Authors:  Guillaume Vincent; Jonathan W Lane; Robert M Williams
Journal:  Tetrahedron Lett       Date:  2007-05-21       Impact factor: 2.415

7.  Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice.

Authors:  J H Beumer; N E Franke; R Tolboom; T Buckle; H Rosing; L Lopez-Lazaro; J H M Schellens; J H Beijnen; O van Tellingen
Journal:  Invest New Drugs       Date:  2009-02-24       Impact factor: 3.850

8.  A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors.

Authors:  Meredith K Chuk; Alberta Aikin; Trish Whitcomb; Brigitte C Widemann; Peter Zannikos; Eliel Bayever; Frank M Balis; Elizabeth Fox
Journal:  Pediatr Blood Cancer       Date:  2012-07-27       Impact factor: 3.167

9.  Identification of GAPDH as a protein target of the saframycin antiproliferative agents.

Authors:  Chengguo Xing; Jacob R LaPorte; Joseph K Barbay; Andrew G Myers
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-12       Impact factor: 11.205

10.  Microarray-based transcriptional profiling of renieramycin M and jorunnamycin C, isolated from Thai marine organisms.

Authors:  Kornvika Charupant; Khanit Suwanborirux; Naomi Daikuhara; Masashi Yokoya; Rie Ushijima-Sugano; Takatoshi Kawai; Takashi Owa; Naoki Saito
Journal:  Mar Drugs       Date:  2009-10-19       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.